Tengonermin
Tengonermin (ARENEGYR) is a vascular-targeting agent consisting of the human Tumour Necrosis Factor-α (TNF-α) conjugated with the CNGRCG peptide. Tengonermin increases penetration of intratumoral chemotherapy and T-cell infiltration by modifying the tumour microenvironment[1][2].
Product Specifications
CAS Number
1960461-99-7
Product Name Alternative
ARENEGYR; NGR-TNF; NGR-hTNF
UNSPSC
12352203
Target
TNF Receptor
Type
Inhibitory Antibodies
Related Pathways
Apoptosis
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/tengonermin.html
Solubility
H2O
Smiles
[Tengonermin]
References & Citations
[1]Valentinis B, et, al. Mechanism of Action of the Tumor Vessel Targeting Agent NGR-hTNF: Role of Both NGR Peptide and hTNF in Cell Binding and Signaling. Int J Mol Sci. 2019 Sep 12;20 (18) :4511. |[2]Gregorc V, et, al. NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015) : a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 2018 Jun;19 (6) :799-811.
Shipping Conditions
Room temperature
Scientific Category
Inhibitory Antibodies
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
